Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities

doi:10.3748/wjg.v27.i39.6572

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 39

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5028)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

547

WORD

165

HTML

3133

Figures (1-4)

203

Tables (1-2)

201

Sum=4249

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

283

Download

496

Sum=779

Oct 21, 2021 (publication date) through Jul 28, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Oct 21, 2021; 27(39): 6572-6589
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6572

Table 2 Landmark trails on use of neoadjuvant chemotherapy

Study	No. of patients	Treatment arms	Resection rate, %	R0	Median DFS in mo	Median OS in mo
PACT-15[44]	93 Resectable	Surgery + gemcitabine	85	27	4.7	20.4
		Surgery + 6 PEXG	90	37	12.4	26.4
		3PEXG + surgery + 3 PEXG	84	63	16.9	16.9
PREOPANC-01[48]	248 Resectable + BRPC	26Gy/15fr + gemcitabine	60	63	9.9	17.1
PREOPANC-01[48]	248 Resectable + BRPC	Surgery	72	31	7.9	13.7

BRPC: Borderline resectable pancreatic cancer; DFS: Disease-free survival; OS: Overall survival; PEXG: Cisplatin, epirubicin, gemcitabine, and capecitabine.

Citation: Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589
URL: https://www.wjgnet.com/1007-9327/full/v27/i39/6572.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i39.6572